Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290029 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01290029 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 14 participants.
The verdict
NCT01290029, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
Interventions
- DRUG Cinacalcet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-01-25 |
| Est. Completion | 2015-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290029
The ClinicalTrials.gov registry entry for NCT01290029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cinacalcet is the first listed.
NCT01290029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290029 about?
NCT01290029 is a clinical study titled "Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease". The primary objective of the study was to evaluate the safety and tolerability of cinacalcet after a single oral dose in children aged 28 days to less than 6 years with chronic kidney disease receiving dialysis.
What is the current status of trial NCT01290029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-01-25. Estimated completion is 2015-09-23.
What interventions are being tested in trial NCT01290029?
The interventions under investigation include: Cinacalcet (DRUG).
Who is sponsoring clinical trial NCT01290029?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.